nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Sorafenib—liver cancer	0.0347	0.605	CbGbCtD
Trametinib—CYP3A4—Sorafenib—liver cancer	0.0141	0.245	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—liver cancer	0.00855	0.149	CbGbCtD
Trametinib—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00182	0.00451	CcSEcCtD
Trametinib—Gingival bleeding—Epirubicin—liver cancer	0.00182	0.0045	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00179	0.00442	CcSEcCtD
Trametinib—Hypophosphataemia—Epirubicin—liver cancer	0.00177	0.00439	CcSEcCtD
Trametinib—Mucosal inflammation—Doxorubicin—liver cancer	0.00172	0.00427	CcSEcCtD
Trametinib—Pancreatitis—Sorafenib—liver cancer	0.00172	0.00425	CcSEcCtD
Trametinib—Polyp—Epirubicin—liver cancer	0.00169	0.0042	CcSEcCtD
Trametinib—Gingival bleeding—Doxorubicin—liver cancer	0.00168	0.00416	CcSEcCtD
Trametinib—Abdominal discomfort—Sorafenib—liver cancer	0.00168	0.00415	CcSEcCtD
Trametinib—Hypophosphataemia—Doxorubicin—liver cancer	0.00164	0.00406	CcSEcCtD
Trametinib—Folliculitis—Epirubicin—liver cancer	0.00164	0.00406	CcSEcCtD
Trametinib—Neutropenia—Sorafenib—liver cancer	0.00164	0.00405	CcSEcCtD
Trametinib—Hypomagnesaemia—Epirubicin—liver cancer	0.00162	0.00402	CcSEcCtD
Trametinib—Polyp—Doxorubicin—liver cancer	0.00157	0.00388	CcSEcCtD
Trametinib—Infestation NOS—Sorafenib—liver cancer	0.00156	0.00386	CcSEcCtD
Trametinib—Infestation—Sorafenib—liver cancer	0.00156	0.00386	CcSEcCtD
Trametinib—Cyst—Epirubicin—liver cancer	0.00154	0.00382	CcSEcCtD
Trametinib—Renal failure—Sorafenib—liver cancer	0.00153	0.0038	CcSEcCtD
Trametinib—Stomatitis—Sorafenib—liver cancer	0.00152	0.00377	CcSEcCtD
Trametinib—Folliculitis—Doxorubicin—liver cancer	0.00152	0.00376	CcSEcCtD
Trametinib—Hypomagnesaemia—Doxorubicin—liver cancer	0.0015	0.00372	CcSEcCtD
Trametinib—Hypercalcaemia—Epirubicin—liver cancer	0.00148	0.00367	CcSEcCtD
Trametinib—Epistaxis—Sorafenib—liver cancer	0.00147	0.00364	CcSEcCtD
Trametinib—Cyst—Doxorubicin—liver cancer	0.00143	0.00353	CcSEcCtD
Trametinib—Haemoglobin—Sorafenib—liver cancer	0.00141	0.00349	CcSEcCtD
Trametinib—Haemorrhage—Sorafenib—liver cancer	0.0014	0.00347	CcSEcCtD
Trametinib—Vaginal haemorrhage—Epirubicin—liver cancer	0.00139	0.00345	CcSEcCtD
Trametinib—Urinary tract disorder—Sorafenib—liver cancer	0.00138	0.00343	CcSEcCtD
Trametinib—Connective tissue disorder—Sorafenib—liver cancer	0.00138	0.00341	CcSEcCtD
Trametinib—Urethral disorder—Sorafenib—liver cancer	0.00137	0.0034	CcSEcCtD
Trametinib—Hypercalcaemia—Doxorubicin—liver cancer	0.00137	0.0034	CcSEcCtD
Trametinib—Rash erythematous—Epirubicin—liver cancer	0.00135	0.00333	CcSEcCtD
Trametinib—Cardiac disorder—Sorafenib—liver cancer	0.0013	0.00322	CcSEcCtD
Trametinib—Rash pustular—Epirubicin—liver cancer	0.00129	0.0032	CcSEcCtD
Trametinib—Vaginal haemorrhage—Doxorubicin—liver cancer	0.00129	0.00319	CcSEcCtD
Trametinib—Angiopathy—Sorafenib—liver cancer	0.00127	0.00315	CcSEcCtD
Trametinib—Mediastinal disorder—Sorafenib—liver cancer	0.00126	0.00313	CcSEcCtD
Trametinib—Arrhythmia—Sorafenib—liver cancer	0.00125	0.0031	CcSEcCtD
Trametinib—Rash erythematous—Doxorubicin—liver cancer	0.00125	0.00308	CcSEcCtD
Trametinib—Mental disorder—Sorafenib—liver cancer	0.00123	0.00304	CcSEcCtD
Trametinib—Malnutrition—Sorafenib—liver cancer	0.00122	0.00302	CcSEcCtD
Trametinib—Erythema—Sorafenib—liver cancer	0.00122	0.00302	CcSEcCtD
Trametinib—Neoplasm malignant—Epirubicin—liver cancer	0.00121	0.00299	CcSEcCtD
Trametinib—Rash pustular—Doxorubicin—liver cancer	0.0012	0.00296	CcSEcCtD
Trametinib—Dysgeusia—Sorafenib—liver cancer	0.00119	0.00296	CcSEcCtD
Trametinib—Muscle spasms—Sorafenib—liver cancer	0.00117	0.0029	CcSEcCtD
Trametinib—Rectal haemorrhage—Epirubicin—liver cancer	0.00114	0.00283	CcSEcCtD
Trametinib—Bone disorder—Epirubicin—liver cancer	0.00114	0.00283	CcSEcCtD
Trametinib—Cellulitis—Epirubicin—liver cancer	0.00113	0.00281	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00113	0.00281	CcSEcCtD
Trametinib—Anaemia—Sorafenib—liver cancer	0.00113	0.00279	CcSEcCtD
Trametinib—Hypocalcaemia—Epirubicin—liver cancer	0.00113	0.00279	CcSEcCtD
Trametinib—Neoplasm malignant—Doxorubicin—liver cancer	0.00112	0.00277	CcSEcCtD
Trametinib—Leukopenia—Sorafenib—liver cancer	0.00109	0.0027	CcSEcCtD
Trametinib—Creatinine increased—Epirubicin—liver cancer	0.00108	0.00268	CcSEcCtD
Trametinib—Cough—Sorafenib—liver cancer	0.00106	0.00263	CcSEcCtD
Trametinib—Bone disorder—Doxorubicin—liver cancer	0.00106	0.00261	CcSEcCtD
Trametinib—Rectal haemorrhage—Doxorubicin—liver cancer	0.00106	0.00261	CcSEcCtD
Trametinib—Hypertension—Sorafenib—liver cancer	0.00105	0.00261	CcSEcCtD
Trametinib—Cellulitis—Doxorubicin—liver cancer	0.00105	0.0026	CcSEcCtD
Trametinib—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.00105	0.0026	CcSEcCtD
Trametinib—Hypocalcaemia—Doxorubicin—liver cancer	0.00104	0.00258	CcSEcCtD
Trametinib—Arthralgia—Sorafenib—liver cancer	0.00104	0.00257	CcSEcCtD
Trametinib—Myalgia—Sorafenib—liver cancer	0.00104	0.00257	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00103	0.00255	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Epirubicin—liver cancer	0.00103	0.00255	CcSEcCtD
Trametinib—Dry mouth—Sorafenib—liver cancer	0.00102	0.00251	CcSEcCtD
Trametinib—Hyperkalaemia—Epirubicin—liver cancer	0.00101	0.00251	CcSEcCtD
Trametinib—Melaena—Epirubicin—liver cancer	0.00101	0.00249	CcSEcCtD
Trametinib—Creatinine increased—Doxorubicin—liver cancer	0.001	0.00248	CcSEcCtD
Trametinib—Infection—Sorafenib—liver cancer	0.000989	0.00245	CcSEcCtD
Trametinib—Nervous system disorder—Sorafenib—liver cancer	0.000976	0.00242	CcSEcCtD
Trametinib—Thrombocytopenia—Sorafenib—liver cancer	0.000974	0.00241	CcSEcCtD
Trametinib—Skin disorder—Sorafenib—liver cancer	0.000966	0.00239	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000954	0.00236	CcSEcCtD
Trametinib—Dry eye—Epirubicin—liver cancer	0.000952	0.00236	CcSEcCtD
Trametinib—Hyperkalaemia—Doxorubicin—liver cancer	0.000937	0.00232	CcSEcCtD
Trametinib—Rash maculo-papular—Epirubicin—liver cancer	0.000937	0.00232	CcSEcCtD
Trametinib—Neoplasm—Epirubicin—liver cancer	0.000932	0.00231	CcSEcCtD
Trametinib—Mouth ulceration—Epirubicin—liver cancer	0.000932	0.00231	CcSEcCtD
Trametinib—Melaena—Doxorubicin—liver cancer	0.000932	0.00231	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000907	0.00224	CcSEcCtD
Trametinib—Dry eye—Doxorubicin—liver cancer	0.000881	0.00218	CcSEcCtD
Trametinib—Rash maculo-papular—Doxorubicin—liver cancer	0.000867	0.00215	CcSEcCtD
Trametinib—Decreased appetite—Sorafenib—liver cancer	0.000865	0.00214	CcSEcCtD
Trametinib—Neoplasm—Doxorubicin—liver cancer	0.000862	0.00214	CcSEcCtD
Trametinib—Mouth ulceration—Doxorubicin—liver cancer	0.000862	0.00214	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00086	0.00213	CcSEcCtD
Trametinib—Gastrointestinal disorder—Sorafenib—liver cancer	0.000859	0.00213	CcSEcCtD
Trametinib—Fatigue—Sorafenib—liver cancer	0.000858	0.00212	CcSEcCtD
Trametinib—Constipation—Sorafenib—liver cancer	0.000851	0.00211	CcSEcCtD
Trametinib—Cardiac failure congestive—Epirubicin—liver cancer	0.000825	0.00204	CcSEcCtD
Trametinib—Gastrointestinal pain—Sorafenib—liver cancer	0.000814	0.00201	CcSEcCtD
Trametinib—Renal failure acute—Epirubicin—liver cancer	0.00081	0.00201	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000796	0.00197	CcSEcCtD
Trametinib—Abdominal pain—Sorafenib—liver cancer	0.000787	0.00195	CcSEcCtD
Trametinib—Body temperature increased—Sorafenib—liver cancer	0.000787	0.00195	CcSEcCtD
Trametinib—Cardiac failure congestive—Doxorubicin—liver cancer	0.000763	0.00189	CcSEcCtD
Trametinib—Hyponatraemia—Epirubicin—liver cancer	0.000751	0.00186	CcSEcCtD
Trametinib—Renal failure acute—Doxorubicin—liver cancer	0.00075	0.00186	CcSEcCtD
Trametinib—Pain in extremity—Epirubicin—liver cancer	0.000748	0.00185	CcSEcCtD
Trametinib—Asthenia—Sorafenib—liver cancer	0.000714	0.00177	CcSEcCtD
Trametinib—Pruritus—Sorafenib—liver cancer	0.000704	0.00174	CcSEcCtD
Trametinib—Blood creatinine increased—Epirubicin—liver cancer	0.000701	0.00174	CcSEcCtD
Trametinib—Dehydration—Epirubicin—liver cancer	0.000696	0.00172	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—liver cancer	0.000695	0.00172	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—liver cancer	0.000692	0.00171	CcSEcCtD
Trametinib—Dry skin—Epirubicin—liver cancer	0.000686	0.0017	CcSEcCtD
Trametinib—Abdominal pain upper—Epirubicin—liver cancer	0.000683	0.00169	CcSEcCtD
Trametinib—Hypokalaemia—Epirubicin—liver cancer	0.000681	0.00169	CcSEcCtD
Trametinib—Diarrhoea—Sorafenib—liver cancer	0.000681	0.00169	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000674	0.00167	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00066	0.00163	CcSEcCtD
Trametinib—Dizziness—Sorafenib—liver cancer	0.000658	0.00163	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—liver cancer	0.000649	0.00161	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—liver cancer	0.000644	0.00159	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—liver cancer	0.000635	0.00157	CcSEcCtD
Trametinib—Pancreatitis—Epirubicin—liver cancer	0.000634	0.00157	CcSEcCtD
Trametinib—Vomiting—Sorafenib—liver cancer	0.000633	0.00157	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—liver cancer	0.000632	0.00157	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—liver cancer	0.00063	0.00156	CcSEcCtD
Trametinib—Rash—Sorafenib—liver cancer	0.000627	0.00155	CcSEcCtD
Trametinib—Dermatitis—Sorafenib—liver cancer	0.000627	0.00155	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000623	0.00154	CcSEcCtD
Trametinib—Headache—Sorafenib—liver cancer	0.000623	0.00154	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000611	0.00151	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—liver cancer	0.000605	0.0015	CcSEcCtD
Trametinib—Nausea—Sorafenib—liver cancer	0.000591	0.00146	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—liver cancer	0.000587	0.00145	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—liver cancer	0.000583	0.00144	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—liver cancer	0.000577	0.00143	CcSEcCtD
Trametinib—Infestation—Epirubicin—liver cancer	0.000577	0.00143	CcSEcCtD
Trametinib—Renal failure—Epirubicin—liver cancer	0.000567	0.0014	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—liver cancer	0.000562	0.00139	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—liver cancer	0.00056	0.00139	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—liver cancer	0.000559	0.00139	CcSEcCtD
Trametinib—Haematuria—Epirubicin—liver cancer	0.00055	0.00136	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—liver cancer	0.000544	0.00135	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—liver cancer	0.00054	0.00134	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—liver cancer	0.000533	0.00132	CcSEcCtD
Trametinib—Infestation—Doxorubicin—liver cancer	0.000533	0.00132	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—liver cancer	0.000527	0.0013	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—liver cancer	0.000524	0.0013	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—liver cancer	0.00052	0.00129	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—liver cancer	0.00052	0.00129	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—liver cancer	0.000519	0.00128	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—liver cancer	0.000518	0.00128	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—liver cancer	0.000511	0.00127	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—liver cancer	0.00051	0.00126	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—liver cancer	0.000509	0.00126	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—liver cancer	0.000509	0.00126	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—liver cancer	0.000507	0.00126	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—liver cancer	0.000503	0.00125	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—liver cancer	0.000488	0.00121	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—liver cancer	0.000484	0.0012	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—liver cancer	0.000481	0.00119	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—liver cancer	0.00048	0.00119	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—liver cancer	0.000479	0.00119	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—liver cancer	0.000473	0.00117	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—liver cancer	0.000472	0.00117	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—liver cancer	0.000471	0.00117	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—liver cancer	0.00047	0.00116	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—liver cancer	0.000469	0.00116	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—liver cancer	0.000466	0.00116	CcSEcCtD
Trametinib—Chills—Epirubicin—liver cancer	0.000464	0.00115	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—liver cancer	0.000462	0.00115	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—liver cancer	0.000453	0.00112	CcSEcCtD
Trametinib—Erythema—Epirubicin—liver cancer	0.000451	0.00112	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—liver cancer	0.000451	0.00112	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—liver cancer	0.000448	0.00111	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—liver cancer	0.000444	0.0011	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—liver cancer	0.000441	0.00109	CcSEcCtD
Trametinib—Back pain—Epirubicin—liver cancer	0.000436	0.00108	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—liver cancer	0.000435	0.00108	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—liver cancer	0.000433	0.00107	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—liver cancer	0.000432	0.00107	CcSEcCtD
Trametinib—Chills—Doxorubicin—liver cancer	0.00043	0.00106	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—liver cancer	0.000428	0.00106	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—liver cancer	0.000425	0.00105	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—liver cancer	0.00042	0.00104	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—liver cancer	0.000417	0.00103	CcSEcCtD
Trametinib—Erythema—Doxorubicin—liver cancer	0.000417	0.00103	CcSEcCtD
Trametinib—Anaemia—Epirubicin—liver cancer	0.000416	0.00103	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—liver cancer	0.000408	0.00101	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—liver cancer	0.000403	0.000999	CcSEcCtD
Trametinib—Back pain—Doxorubicin—liver cancer	0.000403	0.000999	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—liver cancer	0.000401	0.000993	CcSEcCtD
Trametinib—Cough—Epirubicin—liver cancer	0.000393	0.000974	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—liver cancer	0.000393	0.000973	CcSEcCtD
Trametinib—Hypertension—Epirubicin—liver cancer	0.000389	0.000963	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—liver cancer	0.000385	0.000954	CcSEcCtD
Trametinib—Myalgia—Epirubicin—liver cancer	0.000384	0.00095	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—liver cancer	0.000384	0.00095	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000381	0.000943	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—liver cancer	0.000375	0.000929	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—liver cancer	0.000373	0.000924	CcSEcCtD
Trametinib—Oedema—Epirubicin—liver cancer	0.000368	0.000911	CcSEcCtD
Trametinib—Infection—Epirubicin—liver cancer	0.000365	0.000905	CcSEcCtD
Trametinib—Cough—Doxorubicin—liver cancer	0.000364	0.000901	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—liver cancer	0.000361	0.000893	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—liver cancer	0.00036	0.000892	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—liver cancer	0.00036	0.000891	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—liver cancer	0.000357	0.000885	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—liver cancer	0.000355	0.00088	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—liver cancer	0.000355	0.000879	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—liver cancer	0.000355	0.000879	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000352	0.000873	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—liver cancer	0.000347	0.00086	CcSEcCtD
Trametinib—Oedema—Doxorubicin—liver cancer	0.00034	0.000843	CcSEcCtD
Trametinib—Infection—Doxorubicin—liver cancer	0.000338	0.000837	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000335	0.00083	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—liver cancer	0.000334	0.000826	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—liver cancer	0.000333	0.000825	CcSEcCtD
Trametinib—Insomnia—Epirubicin—liver cancer	0.000333	0.000824	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—liver cancer	0.00033	0.000818	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—liver cancer	0.000329	0.000815	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—liver cancer	0.00032	0.000792	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—liver cancer	0.000317	0.000786	CcSEcCtD
Trametinib—Fatigue—Epirubicin—liver cancer	0.000317	0.000785	CcSEcCtD
Trametinib—Constipation—Epirubicin—liver cancer	0.000314	0.000779	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00031	0.000768	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—liver cancer	0.000308	0.000762	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—liver cancer	0.000301	0.000745	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—liver cancer	0.000296	0.000732	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000294	0.000727	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—liver cancer	0.000293	0.000726	CcSEcCtD
Trametinib—Constipation—Doxorubicin—liver cancer	0.000291	0.000721	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—liver cancer	0.000291	0.00072	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—liver cancer	0.000291	0.00072	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—liver cancer	0.000278	0.000689	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—liver cancer	0.000269	0.000666	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—liver cancer	0.000269	0.000666	CcSEcCtD
Trametinib—Asthenia—Epirubicin—liver cancer	0.000264	0.000653	CcSEcCtD
Trametinib—Pruritus—Epirubicin—liver cancer	0.00026	0.000644	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—liver cancer	0.000252	0.000623	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—liver cancer	0.000244	0.000605	CcSEcCtD
Trametinib—Dizziness—Epirubicin—liver cancer	0.000243	0.000602	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—liver cancer	0.000241	0.000596	CcSEcCtD
Trametinib—Vomiting—Epirubicin—liver cancer	0.000234	0.000579	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—liver cancer	0.000233	0.000577	CcSEcCtD
Trametinib—Rash—Epirubicin—liver cancer	0.000232	0.000574	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—liver cancer	0.000232	0.000574	CcSEcCtD
Trametinib—Headache—Epirubicin—liver cancer	0.00023	0.00057	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—liver cancer	0.000225	0.000557	CcSEcCtD
Trametinib—Nausea—Epirubicin—liver cancer	0.000218	0.000541	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—liver cancer	0.000216	0.000536	CcSEcCtD
Trametinib—Rash—Doxorubicin—liver cancer	0.000215	0.000531	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—liver cancer	0.000214	0.000531	CcSEcCtD
Trametinib—Headache—Doxorubicin—liver cancer	0.000213	0.000528	CcSEcCtD
Trametinib—Nausea—Doxorubicin—liver cancer	0.000202	0.0005	CcSEcCtD
Trametinib—MAP2K1—Disease—MTHFR—liver cancer	3.53e-05	6.55e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—EPT1—liver cancer	3.52e-05	6.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TERT—liver cancer	3.52e-05	6.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CG—liver cancer	3.51e-05	6.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK14—liver cancer	3.46e-05	6.42e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTA1—liver cancer	3.44e-05	6.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TGFB1—liver cancer	3.43e-05	6.36e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—liver cancer	3.42e-05	6.34e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NAT2—liver cancer	3.41e-05	6.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—KRAS—liver cancer	3.39e-05	6.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PRKCE—liver cancer	3.34e-05	6.2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TAT—liver cancer	3.34e-05	6.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CD—liver cancer	3.3e-05	6.13e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.27e-05	6.08e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALDOB—liver cancer	3.27e-05	6.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—liver cancer	3.2e-05	5.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—liver cancer	3.17e-05	5.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APC—liver cancer	3.17e-05	5.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF2—liver cancer	3.16e-05	5.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDH1—liver cancer	3.16e-05	5.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PRKCE—liver cancer	3.12e-05	5.8e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CRABP1—liver cancer	3.11e-05	5.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CD—liver cancer	3.09e-05	5.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CD—liver cancer	3.02e-05	5.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—liver cancer	2.99e-05	5.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—BRAF—liver cancer	2.98e-05	5.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APC—liver cancer	2.96e-05	5.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF2—liver cancer	2.96e-05	5.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDH1—liver cancer	2.95e-05	5.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CSF2—liver cancer	2.95e-05	5.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—RAF1—liver cancer	2.95e-05	5.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—H2AFX—liver cancer	2.91e-05	5.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—liver cancer	2.88e-05	5.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CB—liver cancer	2.88e-05	5.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CD—liver cancer	2.82e-05	5.24e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.8e-05	5.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—liver cancer	2.8e-05	5.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—BRAF—liver cancer	2.79e-05	5.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CD—liver cancer	2.78e-05	5.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CSF2—liver cancer	2.76e-05	5.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—liver cancer	2.76e-05	5.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—RAF1—liver cancer	2.76e-05	5.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SERPINE1—liver cancer	2.75e-05	5.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PIK3CA—liver cancer	2.75e-05	5.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—H2AFX—liver cancer	2.72e-05	5.06e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HPGDS—liver cancer	2.72e-05	5.05e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.71e-05	5.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—liver cancer	2.7e-05	5.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—RAF1—liver cancer	2.69e-05	5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CB—liver cancer	2.69e-05	5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL2—liver cancer	2.64e-05	4.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TERT—liver cancer	2.63e-05	4.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CB—liver cancer	2.63e-05	4.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MTOR—liver cancer	2.63e-05	4.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CD—liver cancer	2.61e-05	4.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—liver cancer	2.58e-05	4.79e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SERPINE1—liver cancer	2.58e-05	4.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—liver cancer	2.57e-05	4.78e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—liver cancer	2.55e-05	4.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—liver cancer	2.55e-05	4.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—RAF1—liver cancer	2.52e-05	4.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—RAF1—liver cancer	2.49e-05	4.61e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2—liver cancer	2.47e-05	4.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1B—liver cancer	2.47e-05	4.58e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.47e-05	4.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TERT—liver cancer	2.46e-05	4.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MTOR—liver cancer	2.46e-05	4.56e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CB—liver cancer	2.46e-05	4.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—liver cancer	2.44e-05	4.52e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.43e-05	4.52e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MTOR—liver cancer	2.43e-05	4.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CB—liver cancer	2.43e-05	4.5e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PSMD10—liver cancer	2.43e-05	4.5e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PSMA4—liver cancer	2.43e-05	4.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—liver cancer	2.41e-05	4.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KDR—liver cancer	2.41e-05	4.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK14—liver cancer	2.39e-05	4.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—liver cancer	2.38e-05	4.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—liver cancer	2.38e-05	4.42e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GOT2—liver cancer	2.36e-05	4.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—JUN—liver cancer	2.35e-05	4.36e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ESR1—liver cancer	2.35e-05	4.36e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTNNB1—liver cancer	2.33e-05	4.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—RAF1—liver cancer	2.33e-05	4.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—F2—liver cancer	2.32e-05	4.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1B—liver cancer	2.31e-05	4.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—liver cancer	2.28e-05	4.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1B—liver cancer	2.28e-05	4.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1A—liver cancer	2.28e-05	4.23e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTOR—liver cancer	2.27e-05	4.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CB—liver cancer	2.27e-05	4.21e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CPT1B—liver cancer	2.27e-05	4.21e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GLUL—liver cancer	2.27e-05	4.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—liver cancer	2.26e-05	4.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KDR—liver cancer	2.25e-05	4.18e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—liver cancer	2.25e-05	4.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK14—liver cancer	2.24e-05	4.15e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK8—liver cancer	2.22e-05	4.12e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP2E1—liver cancer	2.22e-05	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APC—liver cancer	2.22e-05	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—liver cancer	2.22e-05	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—JUN—liver cancer	2.2e-05	4.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ESR1—liver cancer	2.2e-05	4.07e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NR1H4—liver cancer	2.19e-05	4.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—liver cancer	2.18e-05	4.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—F2—liver cancer	2.17e-05	4.02e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—liver cancer	2.15e-05	3.99e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA3—liver cancer	2.15e-05	3.99e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.15e-05	3.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1B—liver cancer	2.13e-05	3.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1A—liver cancer	2.13e-05	3.95e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—liver cancer	2.1e-05	3.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1A—liver cancer	2.1e-05	3.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—liver cancer	2.09e-05	3.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK8—liver cancer	2.08e-05	3.86e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYCS—liver cancer	2.08e-05	3.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APC—liver cancer	2.08e-05	3.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—liver cancer	2.08e-05	3.85e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GGT1—liver cancer	2.04e-05	3.78e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GOT1—liver cancer	2.04e-05	3.78e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—liver cancer	2.03e-05	3.77e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—liver cancer	2.01e-05	3.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1A—liver cancer	1.97e-05	3.65e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA4—liver cancer	1.97e-05	3.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—liver cancer	1.95e-05	3.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CD—liver cancer	1.95e-05	3.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SERPINE1—liver cancer	1.93e-05	3.58e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA2—liver cancer	1.92e-05	3.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—liver cancer	1.91e-05	3.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—liver cancer	1.9e-05	3.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—liver cancer	1.88e-05	3.48e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA1—liver cancer	1.85e-05	3.43e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—liver cancer	1.83e-05	3.4e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NAT2—liver cancer	1.83e-05	3.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CD—liver cancer	1.82e-05	3.39e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HMOX1—liver cancer	1.81e-05	3.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SERPINE1—liver cancer	1.8e-05	3.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—liver cancer	1.79e-05	3.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—liver cancer	1.75e-05	3.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—liver cancer	1.75e-05	3.26e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALDOB—liver cancer	1.75e-05	3.25e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—liver cancer	1.74e-05	3.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—liver cancer	1.74e-05	3.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RAF1—liver cancer	1.74e-05	3.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—liver cancer	1.74e-05	3.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MTOR—liver cancer	1.7e-05	3.15e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CB—liver cancer	1.7e-05	3.15e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTM1—liver cancer	1.68e-05	3.12e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CRABP1—liver cancer	1.67e-05	3.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—liver cancer	1.64e-05	3.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—liver cancer	1.63e-05	3.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—liver cancer	1.63e-05	3.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAF1—liver cancer	1.63e-05	3.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—liver cancer	1.63e-05	3.02e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—liver cancer	1.62e-05	3.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—liver cancer	1.61e-05	2.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—liver cancer	1.6e-05	2.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1B—liver cancer	1.6e-05	2.96e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1A1—liver cancer	1.59e-05	2.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MTOR—liver cancer	1.59e-05	2.95e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CB—liver cancer	1.59e-05	2.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—liver cancer	1.56e-05	2.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—liver cancer	1.56e-05	2.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—liver cancer	1.55e-05	2.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—liver cancer	1.52e-05	2.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JUN—liver cancer	1.52e-05	2.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—liver cancer	1.52e-05	2.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—liver cancer	1.51e-05	2.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—liver cancer	1.51e-05	2.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—liver cancer	1.5e-05	2.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1B—liver cancer	1.49e-05	2.77e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MTHFR—liver cancer	1.49e-05	2.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—liver cancer	1.48e-05	2.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—liver cancer	1.48e-05	2.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—liver cancer	1.48e-05	2.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1A—liver cancer	1.47e-05	2.73e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—liver cancer	1.46e-05	2.71e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HPGDS—liver cancer	1.46e-05	2.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—liver cancer	1.46e-05	2.71e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARA—liver cancer	1.46e-05	2.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—liver cancer	1.45e-05	2.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK8—liver cancer	1.44e-05	2.67e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—liver cancer	1.43e-05	2.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—liver cancer	1.42e-05	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JUN—liver cancer	1.42e-05	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—liver cancer	1.42e-05	2.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—liver cancer	1.41e-05	2.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—liver cancer	1.39e-05	2.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—liver cancer	1.38e-05	2.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—liver cancer	1.38e-05	2.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1A—liver cancer	1.38e-05	2.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—liver cancer	1.37e-05	2.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK8—liver cancer	1.34e-05	2.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—liver cancer	1.34e-05	2.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—liver cancer	1.33e-05	2.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—liver cancer	1.33e-05	2.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—liver cancer	1.31e-05	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—liver cancer	1.31e-05	2.43e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.31e-05	2.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—liver cancer	1.31e-05	2.43e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PSMA4—liver cancer	1.3e-05	2.42e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PSMD10—liver cancer	1.3e-05	2.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—liver cancer	1.28e-05	2.38e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GOT2—liver cancer	1.27e-05	2.35e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—liver cancer	1.25e-05	2.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—liver cancer	1.24e-05	2.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—liver cancer	1.23e-05	2.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—liver cancer	1.23e-05	2.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—liver cancer	1.22e-05	2.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—liver cancer	1.22e-05	2.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—liver cancer	1.22e-05	2.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—liver cancer	1.21e-05	2.24e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARG—liver cancer	1.21e-05	2.24e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2E1—liver cancer	1.19e-05	2.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—liver cancer	1.14e-05	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—liver cancer	1.14e-05	2.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—liver cancer	1.13e-05	2.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—liver cancer	1.13e-05	2.09e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYCS—liver cancer	1.11e-05	2.07e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CD—liver cancer	1.1e-05	2.04e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GGT1—liver cancer	1.09e-05	2.03e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GOT1—liver cancer	1.09e-05	2.03e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALB—liver cancer	1.08e-05	2.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—liver cancer	1.06e-05	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—liver cancer	1.04e-05	1.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—liver cancer	1e-05	1.86e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—liver cancer	9.82e-06	1.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—liver cancer	9.69e-06	1.8e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HMOX1—liver cancer	9.69e-06	1.8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—liver cancer	9.59e-06	1.78e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CB—liver cancer	9.57e-06	1.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—liver cancer	9.38e-06	1.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—liver cancer	9.18e-06	1.7e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTM1—liver cancer	9.03e-06	1.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—liver cancer	8.97e-06	1.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—liver cancer	8.58e-06	1.59e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1A1—liver cancer	8.56e-06	1.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—liver cancer	8.46e-06	1.57e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTHFR—liver cancer	7.98e-06	1.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—liver cancer	7.92e-06	1.47e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARA—liver cancer	7.83e-06	1.45e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—liver cancer	6.7e-06	1.24e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARG—liver cancer	6.47e-06	1.2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CD—liver cancer	5.89e-06	1.09e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—liver cancer	5.83e-06	1.08e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALB—liver cancer	5.82e-06	1.08e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CB—liver cancer	5.14e-06	9.53e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—liver cancer	4.77e-06	8.85e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—liver cancer	3.13e-06	5.81e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—liver cancer	2.56e-06	4.75e-06	CbGpPWpGaD
